(Q51127693)

30 March 2018

title

Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. (English)

1 reference

30 March 2018

0 references

6

1 reference

30 March 2018

author name string

Ajay Tejwani

1

1 reference

30 March 2018

Shenhong Wu

2

1 reference

30 March 2018

Yuxia Jia

3

1 reference

30 March 2018

Mark Agulnik

4

1 reference

30 March 2018

Laura Millender

5

1 reference

30 March 2018

language of work or name

English

0 references

publication date

1 March 2009

1 reference

30 March 2018

published in

Cancer

1 reference

30 March 2018

volume

115

1 reference

30 March 2018

issue

6

1 reference

30 March 2018

page(s)

1286-1299

1 reference

30 March 2018

Quantitative synthesis in systematic reviews

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Severe cutaneous reaction during radiation therapy with concurrent cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Cetuximab is effective, but more toxic than reported in the Bonner trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Temporal dependence of the effect of radiation on erlotinib-induced skin rash

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Mechanisms of cutaneous toxicities to EGFR inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24120

7 January 2021

Identifiers

DOI

10.1002/CNCR.24120

1 reference

30 March 2018

PubMed ID

19170238

1 reference

30 March 2018